[ad_1]
According to professor of medicine Saulius Čaplinskas, Janssen was developed using the same platform as the AstraZeneca vaccine. It is true that, compared to him, the Johnson & Johnson course consists of a single puncture. This is one of the benefits of this vaccine. On the other hand, according to the interlocutor, it is very likely that a reinjection will be needed in the near future.
“Nobody said that a booster would be necessary. It’s just that the first course of the vaccine is a vaccine, and all other vaccines, the first course consists of two pricks with a certain time interval,” said a specialist in the program 15 /fifteen.
Another Johnson & Johnson advantage could be the lower sensitivity to environmental conditions when, for example, Comirnaty and Moderna vaccines require extremely low temperatures.
Perhaps it is too exaggerated in those varieties.
On the other hand, the vaccine has its drawbacks. One of them is a slightly minor impact. Studies show that after a single injection, Janssen’s effectiveness in preventing COVID-19 is about 66%, and in extremely severe forms of the disease, 85%. When the Pfizer and Biontech and Moderna vaccines are more than 90% effective.
Another disadvantage could be identified as more frequent side effects in younger people and relatively fewer effects in increasingly emerging strains. It is true that, according to the specialist, this last characteristic is common to all vaccines, and in the future the variety will increase.
“It just came to our knowledge then. This is important for a specialist, it does not change anything for an ordinary person. Prevention and protection measures remain the same. The vaccine must be used as is. Then, the task of scientists is to monitor : if the virus is modified in such a way that one or another vaccine is not effective enough, how to improve it and modify it as soon as possible to keep up with the virus. And that the virus is changing and changing, it was clear from the beginning ” said S. Čaplinskas on the program “15/15”.
Janssen is the fourth COVID-19 vaccine registered in the European Union. The first shipment of this vaccine (4800 doses) arrived in Lithuania on April 13. However, the manufacturer has asked that the vaccine be discontinued until rare cases of side effects are investigated in the United States.
VIDEO: 15/15: Johnson & Johnson Vaccine Launch – What are its advantages and disadvantages?
US health officials reported eight cases of blood clots among people vaccinated with Johnson & Johnson last week, one of which resulted in death, BNS reports.
Questions about blood clots have also been raised with the AstraZeneca vaccine, which is manufactured using technology similar to that of the Johnson & Johnson vaccine. In Lithuania and the European Union, vaccination with AstraZeneca was temporarily suspended in mid-March due to identified cases of thromboembolism in vaccinated people.
In early April, the EVA said that abnormal blood clots should be labeled a ‘very rare’ side effect of AstraZeneca’s pandemic coronavirus vaccine, but noted that the benefits of these vaccines continue to outweigh the potential risks.
So far, the vaccines with Moderna, BioNTech and Pfizer and AstraZeneca have been vaccinated in Lithuania.
[ad_2]
